Wednesday, January 22nd, 2025

SATS: Soaring Above with Strategic Growth and Bullish Market Trends

Date: 28 October 2024
Broker: UOB Kay Hian


Technical Buy Recommendation

UOB Kay Hian has recommended a “Trading Buy” for SATS (SATS SP), based on positive technical indicators. The stock’s current price stands at S$4.01, with an advised trading range of S$3.83–3.84. The broker has set a target price of S$4.32, supported by technical patterns and upward momentum in its market trend.

Technical Indicators Supporting Buy

Several technical indicators suggest a sustained bullish outlook for SATS:

  • Price Above Cloud: SATS is currently trading above the Ichimoku cloud, a signal that the uptrend remains intact.
  • Bullish Crossover: The conversion line and base line have experienced a bullish crossover, further confirming the potential for continued price appreciation.
  • Positive MACD Movement: The Moving Average Convergence Divergence (MACD) is in a rising trend, reinforcing the bullish stance on SATS.

Trade Parameters

To manage downside risk, UOB Kay Hian recommends setting a protective stop at S$3.70. The projected timeframe for this trade idea spans 1–2 weeks, provided the stock reaches the specified entry price within three trading days.

Institutional Research Support

The recommendation is further bolstered by UOB Kay Hian’s institutional research, which also holds a “Fundamental BUY” rating for SATS, with a target price of S$4.00. This aligns the technical buy outlook with a positive long-term fundamental perspective, making SATS a strategically favorable choice for investors.

Singtel plans to pay a total interim dividend of 9.8 cents per share.

Singtel’s Rising Dividends Boost Investor Confidence Amid Strong 1H FY2025 Results Singapore Telecommunications Limited (Singtel) has captured investor optimism as HSBC, UOB Kay Hian (UOBKH), Maybank, RHB, CGS-CIMB, and Citi reaffirm their “buy” recommendations...

Sinopharm Group (1099 HK): Downgrade Amid Weak Revenue Outlook and Policy Challenges

Date of Report: October 29, 2024Broker Name: UOB Kay Hian Company Overview Sinopharm Group (1099 HK) is the largest pharmaceutical distributor in China, operating primarily in healthcare distribution with an extensive network. It has...

CSE Global Expands US Operations: Legal Battle and Strategic Property Sale Signal Growth

Comprehensive Analysis of CSE Global Ltd – UOB Kay Hian Report Comprehensive Analysis of CSE Global Ltd Date of Report: January 7, 2025 Broker: UOB Kay Hian Investment Overview CSE Global Ltd, a prominent...